Product Program year 2025 Source: CMS Open Payments

Pradaxa

Drug Cardiovascular

NDC 0597-0108-60

Open in the dashboard

General payments

$391,911

194 payments

Research payments

$1,514,244

496 payments

Through program year 2025, $391,911 in general payments and $1,514,244 in research payments were reported against Pradaxa (Cardiovascular).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

7 rows
Year Kind Amount Payments
2025 Research $509,402 76
2024 Research $931,656 16
2021 General $14,360 2
2020 General $126,298 46
2020 Research $1,309 78
2019 General $251,253 146
2019 Research $71,876 326

Breakdown

Who paid General payments · program years 2019–2021
  1. Boehringer Ingelheim International GmbH $285,943 166 payments
  2. Boehringer Ingelheim RCV GmbH & Co KG $61,200 5 payments
  3. Boehringer Ingelheim, Unipessoal, Lda. $19,083 4 payments
  4. Boehringer Ingelheim (Phil.) Inc. $14,640 1 payment
  5. Boehringer Ingelheim Canada Ltd.Ltee $4,231 13 payments
  6. Boehringer Ingelheim India PVT. Ltd. $2,360 1 payment
  7. Boehringer Ingelheim Do Brasil Quimica e Farmaceutical Ltda. $1,740 1 payment
  8. Nippon Boehringer Ingelheim Co., Ltd. $1,500 1 payment
  9. Boehringer Ingelheim MENA (Scientific Office) FZ-LLC $1,000 1 payment
  10. Boehringer Ingelheim Pharma GmbH & Co.KG $215 1 payment
Top recipients General payments · program year 2021
  1. Javed Butler Advanced Heart Failure and Transplant Cardiology · Jackson, MS $12,000 84% · 1 payment
  2. Jonathan Halperin Cardiovascular Disease · New York, NY $2,360 16% · 1 payment

Each share is of general payments naming this product in 2021.

Specialties paid General payments · program year 2021
  1. Advanced Heart Failure and Transplant Cardiology Internal Medicine $12,000 84% · 1 practitioner
  2. Cardiovascular Disease Internal Medicine $2,360 16% · 1 practitioner

Each share is of general payments naming this product to practitioners with a specialty in 2021. Each practitioner is counted under their primary specialty.

Where the money went General payments · program year 2021
  1. Mississippi $12,000 84% · 1 recipient
  2. New York $2,360 16% · 1 recipient

Each share is of general payments naming this product in 2021 where a state was reported.

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

409,643

Prescriptions dispensed, refills included

Drug cost

$103,383,213

Paid at the pharmacy, in all

Prescribers

7,474

With 11 or more claims of it

Medicare Part D drugs matched to PRADAXA, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Pradaxa Dabigatran Etexilate Mesylate Same name 7,474 409,643 $103,383,213

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 100 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Jennifer Tresser Pharmacist CA 14,721 $4,197,227 No profile
Huong Ha Pharmacist CA 11,777 $3,395,713 No profile
Carmen Wong Pharmacist CA 9,892 $2,851,484 No profile
Jordan Wong Pharmacist CA 8,618 $2,509,085 No profile
Hyeon Hye Lee Pharmacist CA 7,632 $2,202,146 No profile

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See more in the dashboard: 25 with a free account, all 100 with Patron
194 general · 496 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record